iShares Biotechnology ETF (NASDAQ:IBB) Position Trimmed by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co trimmed its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,093 shares of the financial services provider’s stock after selling 1,175 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in iShares Biotechnology ETF were worth $14,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Proficio Capital Partners LLC acquired a new position in shares of iShares Biotechnology ETF during the 4th quarter worth $480,000. IFP Advisors Inc lifted its position in shares of iShares Biotechnology ETF by 237.1% in the fourth quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock worth $2,118,000 after buying an additional 11,266 shares during the last quarter. FineMark National Bank & Trust bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $319,000. Cullen Frost Bankers Inc. increased its holdings in shares of iShares Biotechnology ETF by 1.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after acquiring an additional 82 shares during the last quarter. Finally, Modern Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at approximately $237,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Up 0.4 %

NASDAQ IBB opened at $118.29 on Monday. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $150.57. The company has a fifty day simple moving average of $129.81 and a 200 day simple moving average of $135.71. The company has a market cap of $5.29 billion, a P/E ratio of 24.21 and a beta of 0.84.

iShares Biotechnology ETF Increases Dividend

The business also recently declared a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were issued a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.